All News

The Medicare payment amount for administering the COVID-19 vaccine is increasing, according to a statement from the Centers for Medicare and Medicaid Services.

The statement from AHA asks primary care physicians to integrate brain health into their treatment of adults guided by the AHA’s Life’s Simple 7.

In addition to prevention with a live attenuated vaccine, treatment options for herpes zoster can include antivirals or symptom management with corticosteroids or analgesics.

A viewpoint perspective from 3 experts endorsed the requirement for a patient and their physician to engage in a shared discussion of benefits and harms before proceeding with a low-dose spiral computed tomography (LDCT) scan in order to prevent lung cancer death.

There have been 15 events of deep vein thrombosis and 22 events of pulmonary embolism reported across the European Union and United Kingdom.

Sodas have significantly high sugar levels and a lack of nutritional value, which may contribute to conditions that can lead to breast cancer.

International Women’s Day serves as a reminder of the role women play in fighting the pandemic and spotlights equity in pay and recognition.

Creating meaningful content on social media can be broken down into 3 steps: planning, creating, and refining.

The increasing prices of the drugs used to treat hookworm, roundworm (ascariasis), and whipworm (trichuriasis) is driving increased costs for patients with Medicaid or private insurance, as well as a potential decrease in the quality of care those patients receive.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Findings show that an inflamed environment allows clostridioides difficile to thrive in an environment that is inhospitable to competing bacteria.

Experts in the management of VTE discuss the deterrents among providers, patients, and pharmacists, specifically looking at the various dosage forms of treatment.

The FDA announced that it will hold a public meeting of the Oncologic Drugs Advisory Committee from April 27 to 29 to address the indications granted accelerated approval for 6 therapies.

Bristol Myers Squibb and bluebird bio are seeking FDA approval for ide-cel as a standard therapy for relapsed myeloma, with a decision expected by the end of March.

A panel of experts discuss the risks vs benefits of prophylactic care for patients to prevent VTE.

The investigators observed a near normal age distribution among patients with long-term COVID-19 symptoms, including children.

Compared to the placebo group, patients with diabetes who received a 54-week course of treatment had higher levels of endogenous insulin secretion with no identified safety concerns.

The pharmaceutical supply chain, while always central to health care, will play an even more crucial role as the pandemic continues to threaten the financial viability of hospitals and health systems, large and small.

The sNDA seeks to expand the label of cabotegravir and rilipivirine to include dosing of every 2 months for the treatment of HIV-1 infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter) on a stable regimen.

The critical component is omega-3 fatty acids, which was associated with a lower risk of major CVD events, such as heart attacks and strokes, by about one-sixth in high-risk people who ate 2 servings of fish rich in omega-3 each week.

Cognitive fatigue, which is defined as a troublesome symptom among healthy and clinical populations, is a major research focus at Kessler Foundation.

Fecal microbiota transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C diff) infections, according to a study by the University of Birmingham.

For millennia, humans have linked feces and disease, making the connection that since it’s gross, it’s probably also harmful.

Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.

Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.

Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.

Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.

Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.

A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.

The FDA has granted a fast track designation to poziotinib for use in previously treated non-small cell lung cancer patients with HER2 exon 20 mutations.